[HTML][HTML] MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and …
TE Arnoff, WS El-Deiry - American Journal of Cancer Research, 2022 - ncbi.nlm.nih.gov
Metastatic melanoma has a five-year survival of~ 10%, with a paucity of biomarkers
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and …
TE Arnoff, WS El-Deiry - American Journal of Cancer Research, 2022 - europepmc.org
Metastatic melanoma has a five-year survival of~ 10%, with a paucity of biomarkers
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
[PDF][PDF] MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and …
TE Arnoff, WS El-Deiry - e-century.us
Metastatic melanoma has a five-year survival of~ 10%, with a paucity of biomarkers
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and …
TE Arnoff, WS El-Deiry - American journal of cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Metastatic melanoma has a five-year survival of~ 10%, with a paucity of biomarkers
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …